Stay updated on Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.

Latest updates to the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page
- Check4 days agoChange DetectedUpdated the “related topics”/glossary area to reflect the sponsor name branding (“Ono Pharmaceutical Co., Ltd.”) and added the associated “Revision: v3.5.3” site version marker, replacing the previous “Revision: v3.5.0” and slightly different formatting.SummaryDifference0.1%

- Check18 days agoChange DetectedThe term 'Melanoma' and the MedlinePlus Genetics related topic reference are removed from the page, diminishing visibility of the study's focus and its related resources.SummaryDifference0.1%

- Check25 days agoChange DetectedLocation entry updated from Padua, Italy to Padova, Italy to reflect local naming.SummaryDifference0.0%

- Check32 days agoChange DetectedAdded Melanoma as a related topic and MedlinePlus Genetics as a related topic. These additions enhance discoverability and contextual navigation without altering the core study details.SummaryDifference0.1%

- Check39 days agoChange DetectedNapoli, Italy, 80131 was updated to Naples, Italy, 80131, and the page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision: v3.4.3 was added; references to Melanoma, MedlinePlus Genetics, and Revision: v3.4.2 were removed. These appear to be administrative updates that do not change the study details or user interactions on the page.SummaryDifference0.1%

Stay in the know with updates to Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.